Related Experiment Video
Updated: May 12, 2026
An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
Published on: December 10, 2013
[Nirsevimab effectiveness against hospital admission for respiratory syncytial virus bronchiolitis in infants]
R Rodríguez-Fernández1, F González-Martínez, I Ojeda Velázquez
1Rosa Rodriguez-Fernández. Sección de Pediatría Interna Hospitalaria. Servicio de Pediatría. Hospital Gregorio Marañón. Calle O'Donnell 50, 28007, Madrid, Spain. rrfernandez@salud.madrid.org.
Insights
Nirsevimab significantly reduced respiratory syncytial virus (RSV) hospital admissions in infants under six months. This new antibody offers 85% effectiveness in preventing RSV bronchiolitis hospitalizations, demonstrating a major impact on infant healthcare.
Area of Science:
- Pediatrics
- Infectious Diseases
- Immunology
Background:
- Respiratory syncytial virus (RSV) bronchiolitis is a primary cause of infant hospitalization.
- Nirsevimab, a long half-life monoclonal antibody, is now available for RSV prevention in infants.
Purpose of the Study:
- To evaluate the impact of Nirsevimab implementation on RSV admissions in infants.
- To assess the effectiveness of Nirsevimab in a real-world hospital setting.
Main Methods:
- An observational, retrospective, and analytical study design was employed.
- Infants under six months admitted for bronchiolitis were analyzed during pre- and post-Nirsevimab periods (September 2015-September 2023 vs. October-December 2023).
- Effectiveness was calculated using the double negative test (1-Odds Ratio) x 100.
Main Results:
- RSV bronchiolitis admissions decreased from 48% to 4.3% in the Nirsevimab era compared to previous seasons (p<0.01).
- Nirsevimab demonstrated 85% effectiveness (95% CI: 32-97%) in preventing RSV hospital admissions in infants under six months.
- No significant differences in bronchiolitis severity were observed between the periods.
Conclusions:
- Nirsevimab implementation significantly reduced hospital admissions for RSV bronchiolitis in infants.
- The study highlights the substantial impact of Nirsevimab on infant hospitalizations due to RSV.
Objective:
Respiratory syncytial virus (RSV) bronchiolitis is the leading cause of hospitalization in infants. This season, a long half-life monoclonal antibody (Nirsevimab) is available to prevent this disease for all infants born from 1 April-30 September to 2023 and all those born during RSV season (October2023- March 2024). The aim of this study was to evaluate the impact of the implementation of this antibody on RSV admissions in a tertiary hospital.
Methods:
Observational, retrospective and analytical study. All patients <6 months in October admitted for bronchiolitis at 2 time points were included: T1 or Pre-nirsevimab time: 1 September 2015-30 September 2023 and T2 or Nirsevimab time: 1 October-31 December 2023. Total admissions due to any cause of infants <6 months in the same period were used as the reference population. To assess the impact of the implementation of nirsevimab, we calculated the reduction in the percentage of admissions due to RSV with respect to total admissions in both periods, and also in the 2023-2024 season we calculated the double negative test to calculate the effectiveness of the intervention (1-Odds ratio) x 100.
Results:
In infants under 6 months of age, we found significant differences in the number of admissions for RSV bronchiolitis between the last season and the previous 7 seasons [574/1195 (48%) vs 6/138 (4.3%); p<0.01, RPI: 91%). In the 2023/2024 season, the effectiveness of nirsevimab in preventing admission for RSV bronchiolitis in children under 6 months of age was 85% (CI 95%: 32-97%).
Conclusions:
The implementation of nirsevimab has had an important impact on the number of hospital admissions for RSV bronchiolitis. There were no differences in the severity of bronchiolitis.
Related Concept Videos
01:17Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:15Upper Respiratory Drugs: First and Second-Generation Antihistamines
Histamine binds to specific receptor sites, known as H1 receptors, on tissue cells, triggering inflammation and swelling. Antihistamines combat these effects by competing with histamine for these receptor sites. By...
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
01:21Acute Respiratory Failure-II
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
01:29Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...